Cargando…

Protein Kinase Inhibitors as Therapeutic Drugs in AML: Advances and Challenges

Acute myeloid leukemia (AML) is a malignant blood disorder and the cure rate has been remarkably improved over the past decade. However, recurrent or refractory leu-kemia remains the major problem of the AML and no clearly effective therapy has been es-tablished so far. Traditional treatments such a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ling, Yuan, Zhang, Zikang, Zhang, Hua, Huang, Zunnan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302345/ https://www.ncbi.nlm.nih.gov/pubmed/28671056 http://dx.doi.org/10.2174/1381612823666170703164114

Ejemplares similares

Protein kinase inhibitors for acute leukemia
por: Ling, Yuan, et al.
Publicado: (2018)

A Review of FLT3 Kinase Inhibitors in AML
por: Negotei, Cristina, et al.
Publicado: (2023)

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
por: Allert, Catana, et al.
Publicado: (2022)

MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells
por: Zeng, Zhihong, et al.
Publicado: (2016)

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer
por: Puisset, Florent, et al.
Publicado: (2023)

AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances
por: Koenig, Kristin L., et al.
Publicado: (2020)

Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
por: van der Kleij, Maud B. A., et al.
Publicado: (2023)

The Challenge of AML in Older Patients
por: Burnett, Alan K
Publicado: (2013)

Advances in therapeutic options for newly diagnosed, high-risk AML patients
por: Doucette, Kimberley, et al.
Publicado: (2021)

New Drugs Bringing New Challenges to AML: A Brief Review
por: Yeoh, Zhi Han, et al.
Publicado: (2021)

Role of Computer-Aided Drug Design in Drug Development
por: Gu, Ruoxu, et al.
Publicado: (2023)

The Role of Therapeutic Leukapheresis in Hyperleukocytotic AML
por: Pastore, Friederike, et al.
Publicado: (2014)

Metabolism-related pharmacokinetic drug−drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations
por: Teo, Yi Ling, et al.
Publicado: (2015)

Natural HDAC‐1/8 inhibitor baicalein exerts therapeutic effect in CBF‐AML
por: Yu, Xiaoxuan, et al.
Publicado: (2020)

Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells
por: Weisberg, Ellen, et al.
Publicado: (2013)

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
por: Verheijen, Remy B., et al.
Publicado: (2017)

Functional Drug Screening of Small Molecule Inhibitors of Epigenetic Modifiers in Refractory AML Patients
por: Dennison, Jessica L., et al.
Publicado: (2022)

Editorial: The latest advances in transplantation for AML
por: Chiusolo, Patrizia, et al.
Publicado: (2023)

Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance
por: Patel, Ravi K., et al.
Publicado: (2019)

How old is old: the beginning of a new era for therapeutic challenges for elderly patients with AML
por: Kim, Hee-Je
Publicado: (2014)

Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery
por: Brar, Harpinder K., et al.
Publicado: (2022)

Advances in RIPK1 kinase inhibitors
por: Chen, Lu, et al.
Publicado: (2022)

Advanced stratification analyses in molecular association meta-analysis: methodology and application
por: Lin, Shuhuang, et al.
Publicado: (2020)

Aberrant splicing and drug resistance in AML
por: de Necochea-Campion, Rosalia, et al.
Publicado: (2016)

Redox metabolism maintains the leukemogenic capacity and drug resistance of AML cells
por: Huang, Dan, et al.
Publicado: (2023)

PB1808: EPIGENETIC INHIBITOR SCREEN TO IDENTIFY THERAPEUTIC CANDIDATES FOR MNX1-OVEREXPRESSING AML
por: Kelekci, Simge, et al.
Publicado: (2023)

Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
por: Wen, Tingyu, et al.
Publicado: (2020)

HLX in AML: novel prognostic and therapeutic target
por: Pandolfi, Ashley, et al.
Publicado: (2012)

Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors
por: Fabro, Federica, et al.
Publicado: (2022)

Utilization of kinase inhibitors as novel therapeutic drug targets: A review
por: NISHAL, SUCHITRA, et al.
Publicado: (2023)

Multi-omics reveals mitochondrial metabolism proteins susceptible for drug discovery in AML
por: Caplan, Mika, et al.
Publicado: (2022)

Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors
por: Yuan, Jie, et al.
Publicado: (2018)

In Silico Methods for Identification of Potential Active Sites of Therapeutic Targets
por: Liao, Jianbo, et al.
Publicado: (2022)

Recent developments of protein kinase inhibitors as potential AD therapeutics
por: Tell, Volkmar, et al.
Publicado: (2013)

CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?
por: Tettamanti, Sarah, et al.
Publicado: (2014)

Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors
por: Lemos, C, et al.
Publicado: (2008)

A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment
por: Long, Jun, et al.
Publicado: (2023)

Mitogen- and stress-activated Kinase 1 mediates Epstein-Barr virus latent membrane protein 1-promoted cell transformation in nasopharyngeal carcinoma through its induction of Fra-1 and c-Jun genes
por: Li, Binbin, et al.
Publicado: (2015)

CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
por: Waldeck, Silvia, et al.
Publicado: (2020)

Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma
por: Chen, Ying-Yi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0610kic2e9r84ajfeflta6asvc